Helmut Butzkueven
Overview
Explore the profile of Helmut Butzkueven including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
324
Citations
7152
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Foong Y, Merlo D, Gresle M, Zhu C, Buzzard K, Lechner-Scott J, et al.
Ann Clin Transl Neurol
. 2025 Feb;
PMID: 40007145
Background: Cognitive impairment is one of the most common and debilitating symptoms of relapsing-remitting multiple sclerosis (RRMS). Digital cognitive biomarkers require less time and resources and are rapidly gaining popularity...
2.
Toscano S, Spelman T, Ozakbas S, Alroughani R, Chisari C, Lo Fermo S, et al.
Neurotherapeutics
. 2025 Feb;
22(2):e00552.
PMID: 39965993
Predicting long-term prognosis and choosing the appropriate therapeutic approach in patients with Multiple Sclerosis (MS) at the time of diagnosis is crucial in view of a personalized medicine. We investigated...
3.
Dhondt R, Dedja K, Aerts S, Van Wijmeersch B, Kalincik T, Reddel S, et al.
Comput Methods Programs Biomed
. 2025 Feb;
263:108624.
PMID: 39965473
Background: Prognostic machine learning research in multiple sclerosis has been mainly focusing on black-box models predicting whether a patients' disability will progress in a fixed number of years. However, as...
4.
Muller J, Sharmin S, Lorscheider J, Horakova D, Kubala Havrdova E, Eichau S, et al.
CNS Drugs
. 2025 Feb;
39(4):403-416.
PMID: 39953338
Background: In relapsing-remitting multiple sclerosis (RRMS), extended exposure to high-efficacy disease modifying therapy may increase the risk of side effects, compromise treatment adherence, and inflate medical costs. Treatment de-escalation, here...
5.
Shipley J, Beharry J, Yeh W, Seery N, Foong Y, Ayton D, et al.
Med J Aust
. 2025 Feb;
PMID: 39923190
Introduction: Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system with rapidly evolving treatment options and strategies. An iterative modified Delphi process was used...
6.
Shipley J, Beharry J, Yeh W, Seery N, Foong Y, Ayton D, et al.
Med J Aust
. 2025 Feb;
PMID: 39923189
Introduction: Multiple sclerosis (MS) is a chronic inflammatory demyelinating and degenerative disease of the central nervous system. There were 33 335 people with MS in Australia in 2021 and 2917...
7.
Foong Y, Merlo D, Gresle M, Zhu C, Buzzard K, Lechner-Scott J, et al.
Eur J Neurol
. 2024 Dec;
32(1):e70000.
PMID: 39714314
Background: Upper limb dysfunction is a common debilitating feature of relapsing-remitting multiple sclerosis (RRMS). We aimed to examine the longitudinal trajectory of the iPad®-based Manual Dexterity Test (MDT) and predictors...
8.
Androdias G, Lunemann J, Maillart E, Amato M, Audoin B, Bruijstens A, et al.
Brain
. 2024 Dec;
PMID: 39707906
The development of disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) has been highly successful in recent decades. It is now widely accepted that early initiation of DMTs...
9.
Aktas O, Ziemssen F, Ziemssen T, Klistorner A, Butzkueven H, Izquierdo G, et al.
Mult Scler Relat Disord
. 2024 Dec;
93:106185.
PMID: 39662163
Background: The randomized, phase 2 RENEW trial (NCT01721161) evaluated efficacy/safety of opicinumab (anti-LINGO-1) versus placebo in patients with first-episode unilateral acute optic neuritis (AON). Although no significant differences in the...
10.
Nesbitt C, van der Walt A, Butzkueven H, Cheung A, Jokubaitis V
Nat Rev Neurol
. 2024 Dec;
21(1):48-62.
PMID: 39658653
Sex and sex hormones are thought to influence multiple sclerosis (MS) through effects on inflammation, myelination and neurodegeneration, and exogenous hormones have been explored for their therapeutic potential. However, our...